接受伏立康唑预防治疗的异基因造血干细胞移植患者侵袭性曲霉病的发病率。
Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
作者信息
Siwek Gregory T, Pfaller Michael A, Polgreen Philip M, Cobb Sandra, Hoth Peter, Magalheas-Silverman Margarida, Diekema Daniel J
机构信息
Program of Hospital Epidemiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
出版信息
Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12. doi: 10.1016/j.diagmicrobio.2006.01.018. Epub 2006 Apr 19.
We performed a retrospective observational study to examine the incidence of invasive aspergillosis (IA) among allogeneic hematopoietic stem cell transplant (HSCT) recipients, according to whether patients received at least 1 week of voriconazole prophylaxis. We report no cases of IA among 92 HSCT recipients who received voriconazole prophylaxis compared with a 10% (23/223) incidence among those receiving other systemic antifungals for prophylaxis (P < .0005).
我们进行了一项回顾性观察研究，以根据患者是否接受了至少1周的伏立康唑预防治疗，来检查异基因造血干细胞移植（HSCT）受者中侵袭性曲霉病（IA）的发生率。我们报告，在接受伏立康唑预防治疗的92例HSCT受者中没有IA病例，而在接受其他全身性抗真菌药物进行预防治疗的患者中，IA发生率为10%（23/223）（P <.0005）。
Zotero 插件